SFAs facilitates ceramide's de novo synthesis via TLR4 and intensifies hepatocyte lipotoxicity.
Level 5 - mechanism / opinion, no new human data
Preclinical animal model (mouse) with mechanistic laboratory analysis.
PubMed 39793229 · doi:10.1016/j.intimp.2025.114020
What was done
Researchers established a non-alcoholic steatohepatitis (NASH) mouse model by feeding mice a palm oil (PO) diet and inducing liver-specific TLR4 knockdown via AAV2/8 tail vein injection. Hepatic damage, steatosis, and inflammation were evaluated using histology, serum ALT and AST, and liver triglyceride measurements. Liquid chromatography-mass spectrometry (LC-MS) was used to quantify hepatic ceramide species, and expression levels of MyD88, serine palmitoyltransferase subunits (SPTLC1, SPTLC2), and inflammatory cytokines (IL-1β, IL-6, TNF-α) were assessed.
What was found
The abstract reports directional changes without specific numerical values. Palm oil feeding elevated serum ALT, AST, and hepatic triglycerides. TLR4 knockdown decreased liver mass, liver-to-body weight ratio, lipid droplet accumulation, and inflammatory infiltrates compared to PO controls. LC-MS showed reductions in specific long-chain ceramides (C14, C16, C20) in TLR4-knockdown mice. Furthermore, expression of MyD88, SPTLC1, SPTLC2, and pro-inflammatory markers (IL-1β, IL-6, TNF-α) was attenuated.
Why it matters
This study delineates a mechanistic link between dietary saturated fatty acids, TLR4/MyD88 signaling, and ceramide de novo synthesis in driving hepatic lipotoxicity. Targeting this pathway may offer therapeutic avenues for managing fatty liver disease progression.
Limits
The study is restricted to a rodent model, so findings cannot be directly applied to human clinical settings without validation. The abstract does not report the number of animals used, baseline parameters, effect sizes, or variance measures. Additionally, the experimental model relies on high-dose palm oil feeding and viral gene knockdown, which may not fully replicate chronic human metabolic disease.
Cited by
- supports Palmitate directly activates TLR4 (Toll-like receptor 4), which subsequently drives the synthesis of ceramides.